<DOC>
	<DOCNO>NCT01016392</DOCNO>
	<brief_summary>Kuvan® synthetic copy body 's substance call tetrahydrobiopterin ( BH4 ) . BH4 require body use amino acid call phenylalanine order build another substance call tyrosine . Kuvan® receive marketed authorisation Europe December 2008 available several European country treatment Hyperphenylalaninemia ( HPA ) . The primary objective ass long-term safety subject treat Kuvan® . Secondary objective provide additional information regarding : - Safety specific subject group ( elderly , pediatric , pregnant woman subject renal hepatic insufficiency ) . - Growth neurocognitive outcome subject hyperphenylalaninemia ( HPA ) receive treatment Kuvan® . - Progress outcome pregnancy woman HPA become pregnant receive treatment Kuvan® ( woman enrol dedicated sub-registry ) . - Assessment adherence diet Kuvan® . - Assessment long-term sensitivity Kuvan®treatment .</brief_summary>
	<brief_title>Observational Study Long Term Safety Kuvan® Treatment Patients With Hyperphenylalaninemia ( HPA ) Due Phenylketonuria ( PKU ) BH4 Deficiency</brief_title>
	<detailed_description>This observational , multicenter , drug registry Study . The study total duration 15 year , include 10-year inclusion period . No diagnostic , therapeutic experimental intervention involve . Subjects receive clinical assessment , medication treatment solely determine study physician .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<criteria>• Adult pediatric subject ( 4 year old old ) either gender HPA due PKU . Or Adult pediatric subject ( low limit age ) either gender HPA due BH4 deficiency Have show responsive BH4 Kuvan . ( Note : For Spain onlyHave show responsive BH4 newly diagnose subject responsive Kuvan define Summary Product Characteristics [ SmPC ] ) Currently treat Kuvan® participate centre Subject parent/legal guardian willing able provide write sign informed consent give data collection . If child old enough read write , separate assent form give Have show responsive BH4 newly diagnose subject fo responsive Kuvan define SmPC Known hypersensitivity Kuvan® Legal incapacity limit legal capacity without legal guardian representation Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Observational post-authorization safety study Kuvan® .</keyword>
</DOC>